AGC Biologics, a global biopharmaceutical contract development and manufacturing organization (CDMO), has announced a development and manufacturing services agreement with Adaptimmune, a cell therapy company focused on solid tumors. Under the agreement, AGC Biologics will manufacture the lentiviral vector used to produce lete-cel, an engineered T-cell therapy targeting the NY-ESO-1 antigen. This support will include activities crucial for Adaptimmune’s regulatory submissions, such as pr...